|
|
| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Trichomonas vaginalis PCR, Cytology
T. vaginalis
Trich
MessageIntended for the dection of Trichomonas vaginalis from an enocervical, vaginal, or male urethral swab or specimen in Thin Prep vial
Test Code
TRCYT
Alias/See Also
0001342
CPT Codes
87661
Preferred Specimen
Thin prep vial
Aptima Unisex or Multitest Collection kit from endocervical, vaginal or male urethral swab
Aptima Unisex or Multitest Collection kit from endocervical, vaginal or male urethral swab
Minimum Volume
1 Thin prep vial
1 swab
1 swab
Transport Container
Thin Prep vial
Aptima Vaginal collection kit
Multitest collection kit
Aptima Vaginal collection kit
Multitest collection kit
Transport Temperature
Room temperature or refrigerated
2°C-30°C
Specimen Stability
Swab in transport tube - 60 day at room temperature
Thin prep vial - 30 days when store at 2°C-30°C
Thin prep vial - 30 days when store at 2°C-30°C
Methodology
Transcription-Mediated Amplification (TMA)
Setup Schedule
Monday-Friday
Reference Range
See patient report for interpretation of results.
Clinical Significance
Trichomoniasis is one of the most common sexually transmitted infections (STIs) in the United States, with an estimated 1.1 million new cases each year [3]. It is curable. About 70% of people infected with T. vaginalis are asymptomatic, though symptoms may show up after the infection has been present for some time. In women, symptoms include vaginal and/or urethral discharge, painful urination, and genital burning and discomfort [4].
In women, untreated T. vaginalis infection can lead to infertility, pelvic inflammatory disease, and cervical neoplasia. T. vaginalis infection is associated with a 2- to 3-fold increased risk for HIV infection in women, as well as increased risk of preterm labor [1].
T. vaginalis testing is recommended for women with vaginal discharge or cervicitis [4]. Because of the high rate of reinfection in individuals treated for T. vaginalis, repeat testing 3 months after treatment is recommended. Additionally, screening is recommended for HIV-infected women at the first HIV-related visit, with follow-up T. vaginalis testing annually. For pregnant women with HIV infection, T. vaginalis screening is recommended at the first prenatal visit [1].
A "detected" result is consistent with T. vaginalis infection. False-positive results could be obtained from sampling less than 2 weeks after cessation of therapy, since TMA-based tests can detect nucleic acids from dead organisms. A "not detected" result is consistent with the absence of T. vaginalis infection. False-negative results could be obtained due to an organism concentration below the assay detection limit [1].
In women, untreated T. vaginalis infection can lead to infertility, pelvic inflammatory disease, and cervical neoplasia. T. vaginalis infection is associated with a 2- to 3-fold increased risk for HIV infection in women, as well as increased risk of preterm labor [1].
T. vaginalis testing is recommended for women with vaginal discharge or cervicitis [4]. Because of the high rate of reinfection in individuals treated for T. vaginalis, repeat testing 3 months after treatment is recommended. Additionally, screening is recommended for HIV-infected women at the first HIV-related visit, with follow-up T. vaginalis testing annually. For pregnant women with HIV infection, T. vaginalis screening is recommended at the first prenatal visit [1].
A "detected" result is consistent with T. vaginalis infection. False-positive results could be obtained from sampling less than 2 weeks after cessation of therapy, since TMA-based tests can detect nucleic acids from dead organisms. A "not detected" result is consistent with the absence of T. vaginalis infection. False-negative results could be obtained due to an organism concentration below the assay detection limit [1].
Performing Laboratory
Penn Medicine Lancaster General Hospital
